Author:
Vasco Karla A.,Carbonell Samantha,Sloup Rebekah E.,Bowcutt Bailey,Colwell Rita R.,Graubics Karlis,Erskine Ronald,Norby Bo,Ruegg Pamela L.,Zhang Lixin,Manning Shannon D.
Abstract
Abstract
Background
Intramammary (IMM) ceftiofur treatment is commonly used in dairy farms to prevent mastitis, though its impact on the cattle gut microbiome and selection of antibiotic-resistant bacteria has not been elucidated. Herein, we enrolled 40 dairy (Holstein) cows at the end of the lactation phase for dry-cow therapy: 20 were treated with IMM ceftiofur (Spectramast®DC) and a non-antibiotic internal teat sealant (bismuth subnitrate) and 20 (controls) received only bismuth subnitrate. Fecal grab samples were collected before and after treatment (weeks 1, 2, 3, 5, 7, and 9) for bacterial quantification and metagenomic next-generation sequencing.
Results
Overall, 90% and 24% of the 278 samples had Gram-negative bacteria with resistance to ampicillin and ceftiofur, respectively. Most of the cows treated with ceftiofur did not have an increase in the number of resistant bacteria; however, a subset (25%) shed higher levels of ceftiofur-resistant bacteria for up to 2 weeks post-treatment. At week 5, the antibiotic-treated cows had lower microbiota abundance and richness, whereas a greater abundance of genes encoding extended-spectrum β-lactamases (ESBLs), CfxA, ACI-1, and CMY, was observed at weeks 1, 5 and 9. Moreover, the contig and network analyses detected associations between β-lactam resistance genes and phages, mobile genetic elements, and specific genera. Commensal bacterial populations belonging to Bacteroidetes most commonly possessed ESBL genes followed by members of Enterobacteriaceae.
Conclusion
This study highlights variable, persistent effects of IMM ceftiofur treatment on the gut microbiome and resistome in dairy cattle. Antibiotic-treated cattle had an increased abundance of specific taxa and genes encoding ESBL production that persisted for 9 weeks. Fecal shedding of ESBL-producing Enterobacteriaceae, which was classified as a serious public health threat, varied across animals. Together, these findings highlight the need for additional studies aimed at identifying factors associated with shedding levels and the dissemination and persistence of antibiotic resistance determinants on dairy farms across geographic locations.
Publisher
Springer Science and Business Media LLC
Reference69 articles.
1. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399:629–55.
2. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf.
3. U.S. Food and Drug Administration. 2020 Summary Report on Antimicrobials Sold or Distributed for Use in Food-Producing Animals. December 2021. Available at: https://www.fda.gov/media/154820/download.
4. U.S, Food, Drug Administration (FDA). &. Antimicrobial Use and Resistance in animal agriculture the United States, 2016–2019. Summary Report. Center for Veterinary Medicine. June 2022. Available at: https://www.fda.gov/media/159544/download.
5. Gonçalves JL, de Campos JL, Steinberger AJ, Safdar N, Kates A, Sethi A, et al. Incidence and treatments of bovine mastitis and other Diseases on 37 dairy farms in Wisconsin. Pathogens. 2022;11:1282.